AAI Urges Fourth Circuit to Reject Heightened Pleading Requirements and Expansion of Noerr Immunity in Pharmaceutical Monopolization Case (CareFirst v. Amgen)

The American Antitrust Institute (AAI) filed an amicus brief before the U.S. Court of Appeals for the Fourth Circuit in CareFirst of Maryland, Inc. v. Amgen Inc. (No. 26-10394), urging … Continued The post AAI Urges Fourth Circuit to Reject Heightened Pleading Requirements and Expansion of Noerr Immunity in Pharmaceutical Monopolization Case (CareFirst v. Amgen) appeared first on American…